利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

236 条记录 (耗时 0.024 秒)

    Method for the preparation of prostaglandin synthetase
    81.
    发明授权
    Method for the preparation of prostaglandin synthetase 失效
    前列腺素合成酶的制备方法

    公开(公告)号：US4070242A

    公开(公告)日：1978-01-24

    申请号：US780258

    申请日：1977-03-23

    申请人： Sheikh Arshad Saeed

    发明人： Sheikh Arshad Saeed

    IPC分类号： A61K38/53 ,  C07G7/026

    CPC分类号： A61K38/53

    摘要： A method for the preparation of purified prostaglandin synthetase from bovine seminal vesicles is disclosed. The method includes the steps of homogenizing bovine seminal vesicles with a liquid medium to form an homogenate and centrifuging the homogenate at a speed such that the centrifugal force does not exceed 1,000g. The supernatant obtained, containing prostaglandin synthetase, is separated from the solids.

    摘要翻译： 公开了从牛精囊制备纯化的前列腺素合成酶的方法。 该方法包括以下步骤：用液体培养基均匀化牛精液囊泡以形成匀浆并以一定的速度离心匀浆物，使得离心力不超过1,000g。 将得到的含有前列腺素合成酶的上清液与固体分离。

    CIRCULAR RNA MOLECULE AND USE THEREOF IN TARGETED DEGRADATION OF PROTEIN OF INTEREST
    85.
    发明申请
    CIRCULAR RNA MOLECULE AND USE THEREOF IN TARGETED DEGRADATION OF PROTEIN OF INTEREST 有权

    公开(公告)号：US20230042694A1

    公开(公告)日：2023-02-09

    申请号：US17815035

    申请日：2022-07-26

    申请人： Suzhou Curemed Biomedical Technology Co. Ltd.

    发明人： Chijian ZUO ,  Jiali YANG ,  Jiafeng ZHU ,  Yaran DU ,  Yang ZHAO ,  Zhenhua SUN

    IPC分类号： C12N9/00 ,  A61K38/53 ,  A61K48/00

    摘要： The present disclosure belongs to the field of biomedicine. Specifically, the present disclosure relates to a circular RNA molecule, a cyclization precursor RNA molecule, a recombinant nucleic acid molecule, a recombinant expression vector, a recombinant host cell, a composition and use thereof in targeted degradation of a protein of interest, as well as a method for preventing or treating a disease. The circular RNA molecule has good membrane permeability, is easily delivered into cells, and has high-efficiency in vivo protein targeted degradation activity. The circular RNA molecule of the present disclosure successfully achieves inhibition of tumor growth, which proves the in vivo protein degradation activity of bio-PROTACs for the first time, and provides a positive and effective treatment solution for the treatment of diseases such as tumor.

    POLYNUCLEOTIDES ENCODING PROPIONYL-COA CARBOXYLASE ALPHA AND BETA SUBUNITS FOR THE TREATMENT OF PROPIONIC ACIDEMIA
    88.
    发明申请
    POLYNUCLEOTIDES ENCODING PROPIONYL-COA CARBOXYLASE ALPHA AND BETA SUBUNITS FOR THE TREATMENT OF PROPIONIC ACIDEMIA 有权

    公开(公告)号：US20220265856A1

    公开(公告)日：2022-08-25

    申请号：US16765632

    申请日：2018-11-21

    申请人： ModernaTX, Inc.

    发明人： Lei Jiang ,  Lin Tung Guey ,  Paolo G.V. Martini ,  Vladimir Presnyak

    IPC分类号： A61K48/00 ,  A61K38/53 ,  A61K9/127 ,  A61P3/00

    摘要： This disclosure relates to mRNA therapy for the treatment of propionic acidemia (PA). mRNAs for use in the invention, when administered in vivo, encode human propionyl-CoA carboxylase alpha (PCCA) and/or human propionyl-CoA carboxylase beta (PCCB), and isoforms thereof, functional fragments thereof, and fusion proteins comprising PCCA and/or PCCB. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of propionyl-CoA carboxylase (PCC) expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of disease-associated toxic metabolites associated with deficient PCCA or PCCB activity, in subjects.

    MRNA therapy for argininosuccinate synthetase deficiency
    89.
    发明授权
    MRNA therapy for argininosuccinate synthetase deficiency 有权

    公开(公告)号：US11224642B2

    公开(公告)日：2022-01-18

    申请号：US14521351

    申请日：2014-10-22

    申请人： TRANSLATE BIO, INC.

    发明人： Michael Heartlein ,  Frank DeRosa ,  Lianne Smith

    IPC分类号： A61K31/7088 ,  A61K9/127 ,  A61K38/53 ,  C12N9/00 ,  A61K48/00 ,  A61K9/51 ,  A61K31/7105

    摘要： The present invention provides, among other things, methods of treating Argininosuccinate Synthetase Deficiency (ASD), including administering to a subject in need of treatment a composition comprising an mRNA encoding argininosuccinate synthetase (ASS1) at an effective dose and an administration interval such that at least one symptom or feature of ASD is reduced in intensity, severity, or frequency or has delayed in onset. In some embodiments, the mRNA is encapsulated in a liposome comprising one or more cationic lipids, one or more non-cationic lipids, one or more cholesterol-based lipids and one or more PEG-modified lipids.